跳至主要内容
临床试验/NCT00737516
NCT00737516已完成2 期

A Centralized Cord Blood Registry to Facilitate Allogeneic, Unrelated Donor Umbilical Cord Blood Transplantation

National Marrow Donor Program38 个研究点 分布在 1 个国家目标入组 3,621 人开始时间: 2000年1月最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
入组人数
3,621
试验地点
38
主要终点
Study safety and efficacy for treatment for malignant and non-malignant disorders

研究概览

简要总结

The National Marrow Donor Program (NMDP) has established a system for registering, matching, and tracking unrelated donor cord blood units (CBUs) and transplant outcomes. Study subjects are donors who enroll through collaborating cord blood banks. This study creates uniform collection, screening, testing and storage requirements for cord blood units. The purpose of standardization is to improve efficiency in the selection of cord blood units for transplantation.

详细描述

The NMDP Cord Blood registry is organized as a network of member cord blood banks and transplant centers whose interactions are managed by the NMDP's Center for Cord Blood. Banks agree to comply with uniform collection, screening, testing and storage requirements. Upon approval of membership, cord blood banks submit detailed information on each stored CBU for registration into a proprietary computer system. A transplant center, working on behalf of potential recipients, submits search requests to the NMDP and receives electronic reports detailing potentially suitable CBUs. From these reports, the transplant center selects a CBU(s) for further testing, which includes at a minimum confirmation of the CBUs Human Leukocyte Antigen (HLA) typing data. Upon final selection of the desired CBU for transplantation, arrangements are made for timely shipment of the unit to the transplant center. Following transplantation, recipient outcome data are submitted by the transplant center for addition to the study database.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
盲法
None

入排标准

性别
Female
接受健康志愿者

入选标准

  • Pregnancy

排除标准

  • 未提供

研究组 & 干预措施

single arm

Experimental

HPC, Cord Blood

干预措施: HPC, Cord Blood (Biological)

结局指标

主要结局

Study safety and efficacy for treatment for malignant and non-malignant disorders

时间窗: annually

次要结局

  • Study relationship between HLA disparity and survival(annually)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (38)

Loading locations...

相似试验